XML 42 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments - Additional Information (Detail)
€ in Millions
3 Months Ended 5 Months Ended 6 Months Ended
Jun. 28, 2020
USD ($)
Jun. 30, 2019
USD ($)
[1]
Jun. 28, 2020
USD ($)
Jun. 28, 2020
EUR (€)
Debt Instrument [Line Items]        
Discount on debt issue $ 15,300,000   $ 15,300,000  
Debt issuance costs incurred 89,300,000   89,300,000  
Debt issuance costs payable current 22,700,000   22,700,000  
Debt instrument face value 11,489,500,000   11,489,500,000  
Proceeds from term loan facility 11,400,000,000 $ 0 11,478,200,000 [1]  
Line of credit maximum borrowing capacity 4,000,000,000   4,000,000,000  
Line of credit facility terminated 12,000,000,000   12,000,000,000  
Line of Credit Facility, Capacity Available for Specific Purpose 1,500,000,000   1,500,000,000  
Term Loan Facility [Member]        
Debt Instrument [Line Items]        
Debt instrument face value 600,000,000   600,000,000  
Proceeds from term loan facility 600,000,000      
Upjohn [Member]        
Debt Instrument [Line Items]        
Debt instrument face value 7,450,000,000   $ 7,450,000,000  
Upjohn Finance BV [Member]        
Debt Instrument [Line Items]        
Debt instrument face value | €       € 3,600
Pfizer Stockholders [Member] | Term Loan Facility [Member]        
Debt Instrument [Line Items]        
Business combination, partial consideration transferred $ 12,000,000,000      
[1] Represents $11.4 billion of proceeds from the long-term debt issuances in the second quarter of 2020, which are included in Restricted short-term investments in the condensed consolidated balance sheet. For additional information, see Notes 5A. Financial Instruments: Fair Value Measurements and 5B. Financial Instruments: Long-Term Debt.